1h Free Analyst Time
SummarySpeak directly to the analyst to clarify any post sales queries you may have.
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Colorectal Cancer - Pipeline Review, H1 2020, provides an overview of the Colorectal Cancer (Oncology) pipeline landscape.
Colorectal cancer is a cancer that starts in the colon or the rectum. Colorectal cancers begin as a growth called a polyp on the inner lining of the colon or rectum. Symptoms include abdominal pain and tenderness in the lower abdomen, blood in the stool, diarrhea, constipation, change in bowel habits, narrow stools and weight loss with no known reason. Risk factors include smoking, heavy alcohol use, inflammatory bowel disease (IBD) and family history. Treatment includes surgery, radiation therapy and chemotherapy.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Colorectal Cancer - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Colorectal Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Colorectal Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Colorectal Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 7, 30, 217, 239, 1, 16, 290, 56 and 10 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages comprises 2, 24, 11, 1, 37 and 4 molecules, respectively.
Colorectal Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Colorectal Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Colorectal Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Colorectal Cancer (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Colorectal Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Colorectal Cancer (Oncology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Colorectal Cancer (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Colorectal Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Colorectal Cancer - Overview
- Colorectal Cancer - Therapeutics Development
- Colorectal Cancer - Therapeutics Assessment
- Colorectal Cancer - Companies Involved in Therapeutics Development
- Colorectal Cancer - Drug Profiles
- Colorectal Cancer - Dormant Projects
- Colorectal Cancer - Discontinued Products
- Colorectal Cancer - Product Development Milestones
- Appendix
List of Tables
- Number of Products under Development for Colorectal Cancer, H1 2020
- Number of Products under Development by Companies, H1 2020
- Number of Products under Development by Universities/Institutes, H1 2020
- Products under Development by Companies, H1 2020
- Products under Development by Universities/Institutes, H1 2020
- Number of Products by Stage and Target, H1 2020
- Number of Products by Stage and Mechanism of Action, H1 2020
- Number of Products by Stage and Route of Administration, H1 2020
- Number of Products by Stage and Route of Administration, H1 2020 (Contd..1), H1 2020
- Number of Products by Stage and Molecule Type, H1 2020
- Number of Products by Stage and Molecule Type, H1 2020 (Contd..1), H1 2020
- Colorectal Cancer - Pipeline by 3SBio Inc, H1 2020
- Colorectal Cancer - Pipeline by 4D Pharma Plc, H1 2020
- Colorectal Cancer - Pipeline by 4SC AG, H1 2020
- Colorectal Cancer - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H1 2020
- Colorectal Cancer - Pipeline by A2 Biotherapeutics Inc, H1 2020
- Colorectal Cancer - Pipeline by Aadi Bioscience Inc, H1 2020
- Colorectal Cancer - Pipeline by AB Science SA, H1 2020
- Colorectal Cancer - Pipeline by AbbVie Inc, H1 2020
- Colorectal Cancer - Pipeline by AbClon Inc, H1 2020
- Colorectal Cancer - Pipeline by Abcuro Inc, H1 2020
- Colorectal Cancer - Pipeline by ABM Therapeutics Inc, H1 2020
- Colorectal Cancer - Pipeline by Abpro Corp, H1 2020
- Colorectal Cancer - Pipeline by Aclaris Therapeutics Inc, H1 2020
- Colorectal Cancer - Pipeline by Acrotech Biopharma LLC, H1 2020
- Colorectal Cancer - Pipeline by Adamed Sp zoo, H1 2020
- Colorectal Cancer - Pipeline by ADC Therapeutics SA, H1 2020
- Colorectal Cancer - Pipeline by Adlai Nortye Biopharma Co Ltd, H1 2020
- Colorectal Cancer - Pipeline by ADT Pharmaceuticals Inc, H1 2020
- Colorectal Cancer - Pipeline by Aduro BioTech Inc, H1 2020
- Colorectal Cancer - Pipeline by Advanced BioDesign, H1 2020
- Colorectal Cancer - Pipeline by Advaxis Inc, H1 2020
- Colorectal Cancer - Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2020
List of Figures
- Number of Products under Development for Colorectal Cancer, H1 2020
- Number of Products under Development by Companies, H1 2020
- Number of Products under Development by Universities/Institutes, H1 2020
- Number of Products by Top 10 Targets, H1 2020
- Number of Products by Stage and Top 10 Targets, H1 2020
- Number of Products by Top 10 Mechanism of Actions, H1 2020
- Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
- Number of Products by Top 10 Routes of Administration, H1 2020
- Number of Products by Stage and Top 10 Routes of Administration, H1 2020
- Number of Products by Top 10 Molecule Types, H1 2020
- Number of Products by Stage and Top 10 Molecule Types, H1 2020
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- 3SBio Inc
- 4D Pharma Plc
- 4SC AG
- A. Menarini Industrie Farmaceutiche Riunite Srl
- A2 Biotherapeutics Inc
- Aadi Bioscience Inc
- AB Science SA
- AbbVie Inc
- AbClon Inc
- Abcuro Inc
- ABM Therapeutics Inc
- Abpro Corp
- Aclaris Therapeutics Inc
- Acrotech Biopharma LLC
- Adamed Sp zoo
- ADC Therapeutics SA
- Adlai Nortye Biopharma Co Ltd
- ADT Pharmaceuticals Inc
- Aduro BioTech Inc
- Advanced BioDesign
- Advaxis Inc
- Advenchen Laboratories LLC
- Affimed GmbH
- Agency for Science, Technology and Research
- Agenus Inc
- Agilvax Inc
- AIM ImmunoTech Inc
- Akeso Inc
- Alfasigma SpA
- Alkermes Plc
- Alligator Bioscience AB
- Allinky Biopharma SL
- Allist Shanghai Pharmaceutical Technology Co Ltd
- Almac Discovery Ltd
- AlphaMab Co Ltd
- Alphamab Oncology
- Alpine Immune Sciences Inc
- Altimmune Inc
- AltruBio Inc
- ALX Oncology Inc
- Amal Therapeutics SA
- Amarin Corp Plc
- amcure GmbH
- Amgen Inc
- AmMax Bio Inc
- Ampo Biotechnology Inc
- Amrita Therapeutics
- Andes Biotechnologies
- Anew Oncology Inc
- Angex Pharmaceutical Inc
- AnHeart Therapeutics Inc
- Anwita Biosciences Inc
- Apcegen Technologies Pvt Ltd
- APEIRON Biologics AG
- Apexian Pharmaceuticals Inc
- Aphios Corp
- Apogenix AG
- Apollomics Inc
- Apotex Inc
- Aprogen Inc
- Apros Therapeutics Inc
- Araxes Pharma LLC
- Arcus Biosciences Inc
- Argonaut Therapeutics Ltd
- AriBio
- Arisaph Pharmaceuticals Inc
- Arvinas Inc
- Asana BioSciences LLC
- Ascelia Pharma AB
- Ascendis Pharma A/S
- Ascenta Therapeutics Inc
- Ascentage Pharma Group International
- Asclepiumm Taiwan Co Ltd
- Aslan Pharmaceuticals Ltd
- Astellas Pharma Inc
- Astex Pharmaceuticals Inc
- AstraZeneca Plc
- Atreca Inc
- Aurigene Discovery Technologies Ltd
- Aurobindo Pharma Ltd
- B Cell Design SAS
- Bantam Pharmaceutical LLC
- Barricade Therapeutics Corp
- Basilea Pharmaceutica Ltd
- Batu Biologics Inc
- Bavarian Nordic A/S
- Bayer AG
- BeiGene Ltd
- Beijing BGI-GBI Biotech Co Ltd
- Beijing Biostar Technologies Ltd
- Beijing Eastern Biotech Co Ltd
- Beijing Hanmi Pharmaceutical Co Ltd
- Beijing Luzhu Biotechnology Co Ltd
- Beijing Mabworks Biotech Co Ltd
- Benhealth Biopharmaceutical (Shenzhen) Co Ltd
- Betta Pharmaceuticals Co Ltd
- BeyondSpring Inc
- Bicycle Therapeutics Plc
- Bio-Path Holdings Inc
- Bio-Thera Solutions Ltd
- BioAtla LLC
- BIOCND Inc
- Biocon Ltd
- BioCurity Pharmaceuticals Inc
- BioEclipse Therapeutics Inc
- BioIntegrator Ltd
- BioLineRx Ltd
- BioMed Valley Discoveries Inc
- BiomX Inc
- Bionomics Ltd
- BioNTech SE
- Biosceptre International Ltd
- BioXcel Therapeutics Inc
- BioXpress Therapeutics SA
- bluebird bio Inc
- Boehringer Ingelheim International GmbH
- Bold Therapeutics Inc
- Boston Biomedical Inc
- BriaCell Therapeutics Corp
- Bristol-Myers Squibb Co
- Bromodomain Pharmaceuticals Inc
- C4X Discovery Holdings Plc
- Calithera Biosciences Inc
- CanBas Co Ltd
- Cancer Advances Inc
- Cancer Prevention Pharmaceuticals Inc
- Cancer Therapeutics Laboratories Inc
- Canget BioTekpharma LLC
- Cantargia AB
- Cardiff Oncology Inc
- Carna Biosciences Inc
- CaroGen Corp
- Carrick Therapeutics UK Ltd
- CAS-Lamvac Biotech Co Ltd
- CCRP Therapeutics GmbH
- Celldex Therapeutics Inc
- Cellectar Biosciences Inc
- Celleron Therapeutics Ltd
- Cellestia Biotech AG
- Cellivery Therapeutics Inc
- Cellix Bio Pvt Ltd
- Cello Therapeutics Inc
- Celltrion Inc
- Celyad Oncology
- Centus Biotherapeutics Ltd
- Checkmate Pharmaceuticals Inc
- Checkpoint Therapeutics Inc
- ChemoCentryx Inc
- Chengdu Huachuang Biotechnology Co Ltd
- Chengdu Kanghong Pharmaceuticals Group Co Ltd
- Chi Cheung (Shanghai) Biomedical Co Ltd
- Chia Tai Tianqing Pharmaceutical Group Co Ltd
- Chiome Bioscience Inc
- Chipscreen Biosciences Ltd
- ChoDang Pharm Co Ltd
- Chong Kun Dang Pharmaceutical Corp
- Chugai Pharmaceutical Co Ltd
- Cinnagen Co
- Cipla BioTec Pvt Ltd
- Cleveland BioLabs Inc
- Cloaked Therapeutics LLC
- COARE Biotechnology Inc
- Coherent Biopharma
- Compass Therapeutics LLC
- Compugen Ltd
- Corvus Pharmaceuticals Inc
- Cotinga Pharmaceuticals Inc
- CSPC Pharmaceutical Group Ltd
- CStone Pharmaceuticals Co Ltd
- Cue Biopharma Inc
- Curamir Therapeutics Inc
- Curegenix Inc
- Cynvec LLC
- Cytlimic Inc
- Cytodyn Inc
- CytoMed Therapeutics Pte Ltd
- Daiichi Sankyo Co Ltd
- Deciphera Pharmaceuticals Inc
- Decoy Biosystems Inc
- Delta-Fly Pharma Inc
- DevaCell Inc
- Dicerna Pharmaceuticals Inc
- Domain Therapeutics SA
- Domainex Ltd
- Dr. Reddy's Laboratories Ltd
- Dragonboat Biopharmaceutical (Shanghai)Co Ltd
- eFFECTOR Therapeutics Inc
- EirGenix Inc
- Eisai Co Ltd
- Eli Lilly and Co
- Elicio Therapeutics
- EnGeneIC Ltd
- Enochian Biosciences Inc
- EntreChem SL
- Enzene Biosciences Ltd
- Enzo Biochem Inc
- EpicentRx Inc
- Epygen Biotech Pvt Ltd
- Esperas Pharma Inc
- Eternity Bioscience Inc
- Etubics Corp
- Euclises Pharmaceuticals Inc
- Evelo Biosciences Inc
- Evotec SE
- Exelixis Inc
- Exicure Inc
- F. Hoffmann-La Roche Ltd
- Faron Pharmaceuticals Oy
- Fate Therapeutics Inc
- FivePhusion Pty Ltd
- Fog Pharmaceuticals Inc
- Formosa Pharmaceuticals Inc
